Results: LS was 10.7 (6.1-15.7) at baseline, 7.0 (4.8-11.5), 5.3 (4.110.4), 5.3 (3.8-6.5), 4.9 (4.0-5.9), 4.7 (4.0-5.9), at 1 year, 2 years, 3 years, 4 years, 5 (or more) years after initiation of treatment, respectively. The LS at each point after initiation of treatment significantly decreased compared with baseline LS (p<0.0001, p=0.0034, p=0.0001, p=0.0146, p=0.0017, respectively). LS at 2 years significantly decreased compared with 1 year after initiation of treatment (p=0.0177). No significant decrease was observed between baseline LS (22.8; 13.1-29.7) and the last LS measurement (10.7; 7.3-24.2) in the patients
who developed HCC after initiation of treatment (n=5). On the other hand, significant decrease (p<0.0001) was observed between baseline LS (9.3; 6.1-14.8) and the LY2835219 supplier last LS
(5.2; 4.2-7.7) in the patients who did not develop HCC during treatment Apoptosis inhibitor (n=38). Baseline LS and the last LS were significantly higher in the patients with HCC development than those without HCC development (p=0.0089, p=0.0208, respectively). Conclusions: The significant reduction of LS was observed in patients with antiviral treatments, and can be attributed to regression of liver fibrosis. The risk of HCC development was higher in the patients with higher baseline LS and poorer reduction of LS during treatments. Such patients need careful monitoring for the development of HCC. Disclosures: Kentaro Yoshioka – Grant/Research Support: Chugai, Schering-Plough, Bristol Myers Squibb, Tanabe Mitsubishi, Taiho, Otsuka, Ajinomoto, Tore Medical, Urease Torii, Boston„AAScientific The following people have nothing to disclose: Naoto Kawabe, Keisuke Osak-abe, Senju
Hashimoto, Michihito Murao, Yoshifumi Nitta, Takuji Nakano, Hiroaki Shimazaki, Toshiki Kan, Kazunori Nakaoka, Masashi Ohki, Takagawa Yuka, Takamitsu Kurashita, Emi Matsuo, Tomoki Takamura, Aiko Fukui, Toru Nishikawa, Naohiro Ichino Purpose: To observe the long-term antiviral efficacy of telbivu-dine (LdT) administered as a monotherapy and as a combination therapy with adefovir dipivoxil (ADV) for HBeAg-positive chronic hepatitis B (CHB) patients with high ALT level, and investigate the correlation between durability of HBeAg sero-conversion following long-term therapy and virological and serological responses. Methods: A total of 233 drug-naTve HBeAg-positive CHB patients with ALT> 3×ULN and HBV DNA> 105 copies/ml were assigned to receive oral LdT, and ADV was added to an ongoing LdT therapy in patients who had detectable HBV DNA at week 24 and viral rebound during treatment. Consolidation therapy was continued for more than 2 years after achieving HBeAg seroconversion. When HBeAg seroconversion occurred in patients receiving total > 3 years of treatment, the LdT treatment was stopped and they were followed-up for 3 years.